Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 404 | 82 | 315 |
| Samples | 362 | 64 | 296 |
| Peptides | 264 | 45 | 224 |
Function
UGT1A9 · UDP glucuronosyltransferase family 1 member A9
This gene encodes a UDP-glucuronosyltransferase, an enzyme of the glucuronidation pathway that transforms small lipophilic molecules, such as steroids, bilirubin, hormones, and drugs, into water-soluble, excretable metabolites. This gene is part of a complex locus that encodes several UDP-glucuronosyltransferases. The locus includes thirteen unique alternate first exons followed by four common exons. Four of the alternate first exons are considered pseudogenes. Each of the remaining nine 5' exons may be spliced to the four common exons, resulting in nine proteins with different N-termini and identical C-termini. Each first exon encodes the substrate binding site, and is regulated by its own promoter. The enzyme encoded by this gene is active on phenols. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000354728 | O60656 | 404 | 264 |
Gene Properties
Recurrent Mutations
All 263 amino-acid changes on canonical ENST00000354728 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in UGT1A9 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in UGT1A9 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 2/40 5% | 0/0 0% |
| Acute Myeloid Leukemia | 3/90 3% | 0/0 0% |
| Melanoma | 8/210 4% | 59/1899 3% |
| Endometrial Carcinoma | 3/42 7% | 14/612 2% |
| Non-Small Cell Lung Carcinoma | 17/304 6% | 18/1390 1% |
| Colorectal Carcinoma | 4/143 3% | 50/3239 2% |
| Small Cell Lung Carcinoma | 1/9 11% | 10/752 1% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 10/810 1% |
| Glioblastoma | 1/98 1% | 0/0 0% |
| Other Sarcomas | 1/69 1% | 6/699 1% |
| Bladder Carcinoma | 0/58 0% | 9/956 1% |
| Gastric Carcinoma | 0/74 0% | 16/1809 1% |
| Other Solid Cancers | 0/94 0% | 13/1515 1% |
| Hodgkins Lymphoma | 0/16 0% | 1/122 1% |
| Hepatocellular Carcinoma | 5/46 11% | 11/2210 0% |
| Glioma | 0/52 0% | 15/2127 1% |
| Ovarian Carcinoma | 3/109 3% | 4/998 0% |
| Ewings Sarcoma | 1/63 2% | 1/262 0% |
| Esophageal Squamous Cell Carcinoma | 2/51 4% | 13/2550 1% |
| Non-Cancerous | 1/104 1% | 4/830 0% |
| Germ Cell Tumour | 0/25 0% | 1/169 1% |
| Kidney Carcinoma | 2/85 2% | 7/1862 0% |
| Mesothelioma | 1/62 2% | 0/165 0% |
| Head and Neck Carcinoma | 0/85 0% | 6/1574 0% |
| Breast Carcinoma | 3/144 2% | 9/3264 0% |
| Biliary Tract Carcinoma | 0/54 0% | 3/950 0% |
| Neuroendocrine Tumour | 1/154 1% | 1/577 0% |
| Pancreatic Carcinoma | 0/89 0% | 4/1611 0% |
| Cervical Carcinoma | 1/35 3% | 0/422 0% |
| B-Cell Non-Hodgkins Lymphoma | 3/88 3% | 2/2534 0% |
Mutation Distribution
Where UGT1A9 is mutated · all tissues, split by cell line vs tissue
How many mutations in UGT1A9 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 7 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 404 mutations in UGT1A9
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|